Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $21.40.

Several research analysts recently weighed in on STOK shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, August 8th. Wedbush restated an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, September 11th.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in Stoke Therapeutics in the 2nd quarter worth $29,000. Nisa Investment Advisors LLC lifted its stake in Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Stoke Therapeutics in the second quarter valued at $123,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the 1st quarter valued at $141,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares in the last quarter.

Stoke Therapeutics Price Performance

STOK opened at $12.19 on Friday. Stoke Therapeutics has a one year low of $3.35 and a one year high of $17.58. The firm has a market capitalization of $635.35 million, a P/E ratio of -5.06 and a beta of 0.96. The company has a fifty day moving average price of $14.22 and a 200-day moving average price of $13.47.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.33 million. On average, analysts expect that Stoke Therapeutics will post -2.1 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.